Figure 3. Seroresponse in participants with and without MenACWY-CRM after routine vaccinations at 2, 4, 6, and 12 mo. The difference in percentage of seroresponders (95% CI) is shown. (A) Percentage of participants with seroresponse to concomitant vaccinations DTaP-IPV/Hib 1-mo after the 3-dose infant series, at 7 mo. (B) Percentage of participants with seroresponse to pneumococcal conjugate 1-mo after the 3-dose infant series, at 7 mo. (C) Percentage of participants with seroresponse to pneumococcal conjugate 1-mo after the 4th vaccine dose, at 13 mo. *Non-inferiority criteria met for the difference in percentage of seroresponders, i.e., LL95%CI ≥–5% for poliovirus and ≥–10% for all other antigens.